KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Cash & Equivalents (2017 - 2026)

Guardant Health's Cash & Equivalents history spans 9 years, with the latest figure at $378.2 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 28.04% to $378.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $378.2 million, a 28.04% decrease, with the full-year FY2025 number at $378.2 million, down 28.04% from a year prior.
  • Cash & Equivalents hit $378.2 million in Q4 2025 for Guardant Health, down from $580.0 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for GH hit a ceiling of $1.1 billion in Q4 2023 and a floor of $141.6 million in Q4 2022.
  • Historically, Cash & Equivalents has averaged $583.3 million across 5 years, with a median of $576.8 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: plummeted 80.98% in 2022 and later skyrocketed 700.25% in 2023.
  • Tracing GH's Cash & Equivalents over 5 years: stood at $492.2 million in 2021, then crashed by 71.22% to $141.6 million in 2022, then surged by 700.25% to $1.1 billion in 2023, then plummeted by 53.64% to $525.5 million in 2024, then dropped by 28.04% to $378.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for GH at $378.2 million in Q4 2025, $580.0 million in Q3 2025, and $629.1 million in Q2 2025.